VERU INC. (VERU)
$2.82+$0.20 (+7.50%) Today
Loren Mark Katzovitz - Director
Grace Hyun - Director
Lucy Lu - DirectorVeru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 1,800 | $5K |
17 Form 4 filings on record, the earliest from Oct 2, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| K. Gary Barnette - Officer | Open-market purchase | Common Stock | 1,800 | $2.69 | $5K | |
| Mitchell Shuster Steiner - Officer | Grant or award | Common Stock Option | 604,000 | $0.00 | - | |
| Michele Greco - Officer | Grant or award | Common Stock Option | 164,000 | $0.00 | - | |
| Loren Mark Katzovitz - Director | Grant or award | Common Stock Option | 102,000 | $0.00 | - | |
| Grace Hyun - Director | Grant or award | Common Stock Option | 97,000 | $0.00 | - | |
| Michael L. Rankowitz - Director | Grant or award | Common Stock Option | 100,000 | $0.00 | - | |
| Lucy Lu - Director | Grant or award | Common Stock Option | 104,000 | $0.00 | - | |
| K. Gary Barnette - Officer | Grant or award | Common Stock Option | 160,000 | $0.00 | - | |
 Harry Fisch - Officer | Grant or award | Common Stock Option | 160,000 | $0.00 | - | |
| Michael L. Rankowitz - Director | Grant or award | Common Stock Option | 7,000 | $0.00 | - | |
| Lucy Lu - Director | Grant or award | Common Stock Option | 6,000 | $0.00 | - | |
| Grace Hyun - Director | Grant or award | Common Stock Option | 3,000 | $0.00 | - | |
| Mitchell Shuster Steiner - Officer | Grant or award | Common Stock Option | 378,000 | $0.00 | - | |
| Mario Eisenberger - Director | Grant or award | Common Stock Option | 45,000 | $0.00 | - | |
| Grace Hyun - Director | Grant or award | Common Stock Option | 40,000 | $0.00 | - | |
| Lucy Lu - Director | Grant or award | Common Stock Option | 70,000 | $0.00 | - | |
| Michael L. Rankowitz - Director | Grant or award | Common Stock Option | 85,000 | $0.00 | - |
VERU INC. (VERU) had 1 insider filing in the last 90 days, with the most recent on 2026-08-17. The full record for VERU runs to 17 Form 4 filings, the earliest from 2024-10-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
1 insider purchase of VERU was filed in the last 90 days, totaling $5K.
No insider sales of VERU were filed in the last 90 days.
This page tracks VERU Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add VERU to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
